For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
32
views
Article has an altmetric score of 33
13
references
 Top references
cited by
32
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      1,015
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Personalized medicine: risk prediction, targeted therapies and mobile health technology

      Author(s): , , ,
      Publication date (Electronic):
      Journal: BMC Medicine
      Publisher: Springer Science and Business Media LLC

      Read this article at

      ScienceOpenPublisher
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Personalized medicine is increasingly being employed across many areas of clinical practice, as genes associated with specific diseases are discovered and targeted therapies are developed. Mobile apps are also beginning to be used in medicine with the aim of providing a personalized approach to disease management. In some areas of medicine, patient-tailored risk prediction and treatment are applied routinely in the clinic, whereas in other fields, more work is required to translate scientific advances into individualized treatment. In this forum article, we asked specialists in oncology, neurology, endocrinology and mobile health technology to discuss where we are in terms of personalized medicine, and address their visions for the future and the challenges that remain in their respective fields.

          Related collections

          Most cited references13

          • Record: found
          • Abstract: found
          • Article: not found

          Treatment of HER2-positive breast cancer: current status and future perspectives.

          Carlos Arteaga, Mark Sliwkowski, C Osborne … (2011)
          The advent of HER2-directed therapies has significantly improved the outlook for patients with HER2-positive early stage breast cancer. However, a significant proportion of these patients still relapse and die of breast cancer. Trials to define, refine and optimize the use of the two approved HER2-targeted agents (trastuzumab and lapatinib) in patients with HER2-positive early stage breast cancer are ongoing. In addition, promising new approaches are being developed including monoclonal antibodies and small-molecule tyrosine kinase inhibitors targeting HER2 or other HER family members, antibodies linked to cytotoxic moieties or modified to improve their immunological function, immunostimulatory peptides, and targeting the PI3K and IGF-1R pathways. Improved understanding of the HER2 signaling pathway, its relationship with other signaling pathways and mechanisms of resistance has also led to the development of rational combination therapies and to a greater insight into treatment response in patients with HER2-positive breast cancer. Based on promising results with new agents in HER2-positive advanced-stage disease, a series of large trials in the adjuvant and neoadjuvant settings are planned or ongoing. This Review focuses on current treatment for patients with HER2-positive breast cancer and aims to update practicing clinicians on likely future developments in the treatment for this disease according to ongoing clinical trials and translational research.
          Article 0 comments Cited 290 times – based on 0 reviews     Review now
          Article has an altmetric score of 23
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype

            Mohammed Hawa, Hubert Kolb, Nanette Schloot … (2013)
            OBJECTIVE Specific autoantibodies characterize type 1 diabetes in childhood but are also found in adult-onset diabetes, even when initially non–insulin requiring, e.g., with latent autoimmune diabetes (LADA). We aimed to characterize adult-onset autoimmune diabetes. RESEARCH DESIGN AND METHODS We consecutively studied 6,156 European diabetic patients attending clinics within 5 years of diagnosis (age range, 30–70 years) examined cross-sectionally clinically and for GAD antibodies (GADA) and antibodies to insulinoma-associated antigen-2 (IA-2A) and zinc-transporter 8 (ZnT8A). RESULTS Of 6,156 patients, 541 (8.8%) had GADA and only 57 (0.9%) IA-2A or ZnT8A alone. More autoantibody-positive than autoantibody-negative patients were younger, leaner, on insulin (49.5 vs. 13.2%), and female (P 200 World Health Organization IU) (n = 403) compared with low (n = 138) titer were female, lean, and insulin treated (54.6 vs. 39.7%) (P < 0.02 for each). Autoantibody-positive patients usually had GADA (541 of 598; 90.5%) and had LADA more often than type 1 autoimmune diabetes (odds ratio 3.3). CONCLUSIONS Adult-onset autoimmune diabetes emerges as a prevalent form of autoimmune diabetes. Our results indicate that adult-onset autoimmune diabetes in Europe encompasses type 1 diabetes and LADA in the same broad clinical and autoantibody-positive spectrum. At diagnosis, patients with adult-onset autoimmune diabetes are usually non–insulin requiring and clinically indistinguishable from patients with type 2 diabetes, though they tend to be younger and leaner. Only with screening for autoantibodies, especially GADA, can they be identified with certainty.
            Article 0 comments Cited 116 times – based on 0 reviews     Review now
            Article has an altmetric score of 35
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases

              George Beatson (1896)
              Article 0 comments Cited 110 times – based on 0 reviews     Review now
              Article has an altmetric score of 18
                Bookmark
                All references

                Author and article information

                Journal
                Title: BMC Medicine
                Abbreviated Title: BMC Med
                Publisher: Springer Science and Business Media LLC
                ISSN (Electronic): 1741-7015
                Publication date Created: December 2014
                Publication date (Electronic): February 28 2014
                Publication date (Print): December 2014
                Volume: 12
                Issue: 1
                Article
                DOI: 10.1186/1741-7015-12-37
                SO-VID: 0530f04b-6945-4bab-91b2-be6773f8c8b8
                Copyright © © 2014
                License:

                http://www.springer.com/tdm

                History

                Data availability:

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content1,015

                See all similar

                Cited by32

                See all cited by

                Most referenced authors549

                See all reference authors